News Column

Eleven Biotherapeutics Closes Initial Public Offering

February 11, 2014



CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments. Eleven’s common stock began trading on the NASDAQ Global Market under the ticker symbol “EBIO” on February 6, 2014.

Citigroup, Cowen and Company and Leerink Partners LLC are acting as joint book-running managers of the offering. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on February 5, 2014. Copies of the final prospectus relating to this offering can be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by email at batprospectusdept@citi.com, or by phone at (800) 831-9146; Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone at (631) 274-2806, or by fax at (631) 254-7140; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at syndicate@leerink.com, or by phone at (800) 808-7525, ext.4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Eleven Biotherapeutics

Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the company’s understanding of the structural biology of cytokines and the company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.




Eleven Biotherapeutics

Cameron Wheeler, PhD, 617-858-0927

cameron@elevenbio.com

or

Media:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com

Source: Eleven Biotherapeutics


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Business Wire


Story Tools